Beacon Pointe Advisors’s VanEck Pharmaceutical ETF PPH Stock Holding History

Beacon Pointe Advisors’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$393K	Buy	3,592 +4	+0.1%	+$414	﹤0.01%	1460
2026 Q1	$373K	Buy	+3,588	New	+$382K	﹤0.01%	1424
2025 Q3	–	Sell	-2,428	Closed	-$214K	–	1498
2025 Q2	$214K	Hold	2,428	–	–	﹤0.01%	1171
2025 Q1	$221K	Hold	2,428	–	–	﹤0.01%	1122
2024 Q4	$209K	Hold	2,428	–	–	﹤0.01%	1135
2024 Q3	$231K	Hold	2,428	–	–	﹤0.01%	1113
2024 Q2	$222K	Hold	2,428	–	–	﹤0.01%	1160
2024 Q1	$220K	Buy	+2,428	New	+$213K	﹤0.01%	1223
2023 Q2	–	Sell	-3,371	Closed	-$262K	–	1170
2023 Q1	$262K	Buy	3,371 +318	+10%	+$24.5K	﹤0.01%	981
2022 Q4	$237K	Hold	3,053	–	–	﹤0.01%	945
2022 Q3	$207K	Hold	3,053	–	–	﹤0.01%	919
2022 Q2	$235K	Buy	3,053 +350	+13%	+$27.3K	0.01%	917
2022 Q1	$216K	Buy	+2,703	New	+$207K	﹤0.01%	1097

Other funds holding PPH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

JSAM

J. Safra Asset Management New York $2.17B AUM 29.66% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Avalon Trust Santa Fe, New Mexico $1.63B AUM 42.75% 1-Year Est. Return

AWC

Adamsbrown Wealth Consultants Wichita, Kansas $530M AUM 23.21% 1-Year Est. Return

Beacon Pointe Advisors's PPH Position: Q2 2026 in Review

Beacon Pointe Advisors increased its VanEck Pharmaceutical ETF (PPH) stake by 0.11% in Q2 2026, buying an estimated $414 and bringing the position to 3,592 shares worth $393K. The position accounts for ﹤0.01% of the portfolio, ranked #1460.

Beacon Pointe Advisors first reported a position in PPH in Q1 2022 and has held it in 13 quarters since. 148 funds tracked by Wall St. Rank hold PPH as of Q2 2026.

Beacon Pointe Advisors held 3,592 shares of VanEck Pharmaceutical ETF worth $393K as of Q2 2026.
Beacon Pointe Advisors bought 4 VanEck Pharmaceutical ETF shares in Q2 2026, an estimated $414.
VanEck Pharmaceutical ETF made up ﹤0.01% of Beacon Pointe Advisors's portfolio in Q2 2026, its #1460 holding.
Beacon Pointe Advisors first reported a position in VanEck Pharmaceutical ETF in Q1 2022 and has held it in 13 quarters since.
148 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2026.

Based on Beacon Pointe Advisors's 13F filing for Q2 2026, filed 18 Aug 2026.